NEW YORK (GenomeWeb News) — Gene Logic today said it will help Merck Serono, a division of German drug maker Merck, identify alternative development paths for “several” undisclosed drug candidates.
 
All of the candidates were discontinued or “de-prioritized” in clinical trials for reasons other than safety, according to Gene Logic.
 

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have an account?
Login Now.

In a statement, National Institutes of Health Director Francis Collins says sexual harassment is "morally indefensible" and "unacceptable."

Octopuses might owe their intelligence to their liberal alterations to their genes, Cosmos reports.

Stat News and ProPublica report that African Americans are underrepresented in cancer clinical trials.

In Cell this week: genomic analysis of abdominal aortic aneurysm, effect of probiotics on the microbiome, and more.